Ablatus Therapeutics receives first CE Mark for Bimodal Electric Tissue Ablation system component
We are delighted to announce that we have received our first CE mark!
Our surgical ablation system offers significant advantage over the current standard of care across a variety of therapeutic indications. One of the components of the system is a patient grounding pad which facilitates energy delivery into the targeted tissue.
The CE Mark approval indicates that the grounding pad has been developed and manufactured in compliance with the specific standards and requirements of the relevant EU Medical Device Regulations.
Ablatus Therapeutics CEO, David Brooks, said; “We are pleased that the first component of our Bimodal Electric Tissue Ablation system has reached this commercial milestone and further builds on the success in achieving ISO 13485 certification last year. This is an important event in the development of the company, significantly de-risking future development of our ablation system and demonstrating a capability to design and manufacture medical devices.”